🎗️ Abnormal Cervical Screening Management (ASCCP 2019)
Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
Clinical takeaway
ASCCP 2019 shifted from result-based algorithms to 'equal management for equal risk' using immediate and 5-year CIN3+ risk.
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Risk-based management direction for abnormal cervical cancer screening (HPV/co-test) under ASCCP 2019.
How it works
Clinical action by immediate CIN3+ risk: ≥ 60% expedited treatment; 25–< 60% treatment or colposcopy; 4–< 25% colposcopy; < 4% set 1- or 3-year repeat or return to routine by 5-year risk.
Key points
- ASCCP 2019 shifted from result-based algorithms to 'equal management for equal risk' using immediate and 5-year CIN3+ risk.
- The precise risk depends on the current result combined with prior screening history — use the official ASCCP risk-estimator table/App for exact figures.
- HPV+ HSIL reaches a high immediate risk and favours expedited (excisional) treatment without colposcopy in non-pregnant adults.
- HPV+ AGC needs colposcopy + endocervical curettage, with endometrial sampling if ≥ 35 years or abnormal bleeding.
References
- Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Current screening result (HPV triage / co-test) | HPV− and cytology NILM |
|---|
→ManagementReturn to routine screening
- Current result：Immediate CIN3+ risk very low
- Management direction：Return to routine screening (generally 5-yearly co-test or per protocol)
- Clinical action threshold：Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening
| Current screening result (HPV triage / co-test) | HPV+ HSIL |
|---|
→ManagementFavour expedited treatment
- Current result：Immediate CIN3+ ~ 49% (higher if HPV16+)
- Management direction：Favour expedited treatment (excisional, without biopsy); pregnancy / < 25 years / fertility concerns switch to colposcopy
- Clinical action threshold：Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening
Frequently asked questions
- What is Abnormal Cervical Screening Management (ASCCP 2019)?
- Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
- How is Abnormal Cervical Screening Management (ASCCP 2019) calculated? What is the core formula?
- Clinical action by immediate CIN3+ risk: ≥ 60% expedited treatment; 25–< 60% treatment or colposcopy; 4–< 25% colposcopy; < 4% set 1- or 3-year repeat or return to routine by 5-year risk.
- When is Abnormal Cervical Screening Management (ASCCP 2019) used?
- Risk-based management direction for abnormal cervical cancer screening (HPV/co-test) under ASCCP 2019.
- What are the key clinical points for Abnormal Cervical Screening Management (ASCCP 2019)?
- ASCCP 2019 shifted from result-based algorithms to 'equal management for equal risk' using immediate and 5-year CIN3+ risk. The precise risk depends on the current result combined with prior screening history — use the official ASCCP risk-estimator table/App for exact figures. HPV+ HSIL reaches a high immediate risk and favours expedited (excisional) treatment without colposcopy in non-pregnant adults. HPV+ AGC needs colposcopy + endocervical curettage, with endometrial sampling if ≥ 35 years or abnormal bleeding.
- What are the limits and cautions when using Abnormal Cervical Screening Management (ASCCP 2019)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Abnormal Cervical Screening Management (ASCCP 2019) calculated in practice? Can you show a worked example?
- Inputs: Current screening result (HPV triage / co-test) HPV− and cytology NILM → Result: Management Return to routine screening（Current result: Immediate CIN3+ risk very low, Management direction: Return to routine screening (generally 5-yearly co-test or per protocol), Clinical action threshold: Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening） Inputs: Current screening result (HPV triage / co-test) HPV+ HSIL → Result: Management Favour expedited treatment（Current result: Immediate CIN3+ ~ 49% (higher if HPV16+), Management direction: Favour expedited treatment (excisional, without biopsy); pregnancy / < 25 years / fertility concerns switch to colposcopy, Clinical action threshold: Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening）